Young woman holding a Breast Cancer Awareness Ribbon

Benefit of Chemotherapy for Patients With Early-Stage Breast Cancer Varies by Tumor Anatomy

Roswell Park researchers present retrospective analysis of nearly 12,000 cases at AACR annual meeting

  • Team explored whether tumor anatomy was linked to response to treatment
  • Analysis shows benefit of chemo in subgroup with mucinous or medullary tumors
  • Findings support further study in patients with rare histological variants

ORLANDO, Fla. — A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center reports benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or tumor anatomy. These findings will be presented by first author Arya Mariam Roy, MBBS, during the American Association for Cancer Research (AACR) annual meeting, continuing through April 19 in Orlando, Florida.

“The benefit of chemotherapy in the management of rare histological variants of breast cancer, such as mucinous, medullary, cribriform and papillary, is unclear in the current guidelines,” notes Dr. Roy, a Roswell Park hematology/oncology fellow. “Therefore, we queried the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database from 2010-2018 for stage 1, 2 and 3 hormone-receptor-positive HER2-negative breast cancer patients who presented with these rare histological variants and compared the clinical benefits of chemotherapy in patients who received it versus those who did not.”

Alongside study co-lead author Shipra Gandhi, MD, Assistant Professor of Oncology at Roswell Park, and colleagues, Dr. Roy examined overall survival and disease-specific survival in this patient population. Patients were assigned into chemotherapy-positive and chemotherapy-negative cohorts based on whether or not they received adjuvant chemotherapy.

Among 11,745 patients with a mucinous histology, 94 percent were hormone-receptor-positive HER2 negative. Among those individuals, 8.5 percent underwent chemotherapy and 91.5 percent did not. Data showed that the 5-year overall survival rate among all disease stages was higher for those who underwent chemotherapy compared with those who did not. The researchers observed a chemotherapy benefit in 5-year disease-specific survival only among patients with stage 3 breast cancer.

Of the patients with a medullary histology (1,787), 34 percent were hormone-receptor-positive HER2 negative. In this cohort, all patients with stage 3 breast cancer received chemotherapy, and their 5-year overall survival was 94 percent. Among patients with stage 1 and 2 disease, receiving chemotherapy was associated with better 5-year overall survival. The researchers did not see a 5-year disease-specific survival benefit with chemotherapy in any stage.

Ninety-three percent of patients with cribriform tumor anatomy were hormone-receptor-positive HER2 negative. The researchers documented a higher 5-year overall survival rate with chemotherapy in patients with stage 2 disease, but not in those with state 1 or 3 disease. Among patients in the papillary histology group — 83 percent of whom had hormone-receptor-positive HER2 negative disease — treatment with chemotherapy was linked to a better 5-year overall survival at stage 2 alone.

Shipra Gandhi, MD
Dr. Shipra Gandhi

“We observed that in hormone-receptor-positive mucinous and medullary histologies, chemotherapy has an overall survival benefit,” says Dr. Gandhi, a Roswell Park medical oncologist. “In hormone-receptor positive HER2-negative papillary and cribriform histologies, chemotherapy can be considered an option for patients with higher-stage disease. Multicenter clinical trials are needed to further assess the impact of chemotherapy in rare histological variants of breast cancer.”

AACR 2023 Presentation Details

919 /2 - Benefit of chemotherapy in early-stage breast cancer with variant histology
Presenting author: Arya Mariam Roy, MBBS, Roswell Park Comprehensive Cancer Center
Time/date: Sunday, April 16, 2023: 1:30-5 p.m. EDT
Session: PO.CL11.01 - Analyses Using Clinical and Genomic Databases


Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at, or contact us at 1-800-ROSWELL (1-800-767-9355) or



Media Contact

Rebecca Vogt, Media Relations Specialist